



## **Sinclair Pharma**

### **Jerry Randall to step down as Chief Financial Officer**

**23 November 2009, Godalming, UK:** Sinclair Pharma plc (the "Company" or "Sinclair": SPH:L), the international specialty pharma company, today announces that Jerry Randall is to step down as Chief Financial Officer (CFO) at the Company's EGM in early December to pursue other interests and opportunities.

Jerry Randall was appointed CFO of Sinclair Pharma after leading the management buy-in of Sinclair Pharma with Michael Flynn in 2000. During his nine years as CFO, Sinclair has transitioned from a small private UK company into a profitable, international specialty pharma company.

Grahame Cook, Chairman of Sinclair Pharma, said:

"Jerry has been instrumental in building Sinclair Pharma from a standing start into a successful and profitable international specialty pharma company. During this period, Jerry has led the Company through its IPO on AIM, the subsequent move to the London Stock Exchange's Main Market, and its listing on Euronext. He has been involved in raising over £90M for the company and has led a number of significant acquisitions to help build critical mass and a strong sales and marketing presence across Europe resulting in sustained profitability. On behalf of the Board, I would like to thank Jerry for his years of dedication and valuable contribution in building Sinclair Pharma and wish him all the best for the future.

Jerry Randall said:

"Sinclair has grown tremendously in the nine years since we started. I am very proud of our achievements in growing the Company from a standing start into a sustainably profitable, international specialty pharma company. The new management team, planned fund raising and acquisition of products from Solvay will enable Sinclair to maximise the potential in the business and help to progress the company to its next phase of development. It is timely for me to move on to pursue my other interests and opportunities. I would like to thank everyone who has been involved in this journey over the last 9 years for their support, including employees, shareholders and advisers, and I wish them all every success as Sinclair looks towards a truly exciting future ahead."

**- Ends -**

**For further information please contact:**

**Sinclair Pharma plc**  
Chris Spooner  
Dr Michael Flynn

Tel: +44 (0) 1483 410 600



**Singer Capital Markets Ltd**

Shaun Dobson  
Claes Spång

Tel: +44 (0)20 3205 7500

**Capital MS&L**

Mary Clark  
Anna Mitchell

Tel +44 (0)20 7307 5340

**Notes to Editors:**

**About Sinclair Pharma Plc [www.sinclairpharma.com](http://www.sinclairpharma.com)**

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat dermatological, oral care and gynaecological diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is already present in France, Italy and Spain, and a complementary marketing partner network that spans more than 90 countries.

*"Safe Harbour" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.*